HSD17B13 Humanized Mouse Model Advancing MASLD and RNAi Research

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=47X6Oxe5PoE

Join Reza from Cyagen as we explore the innovative HSD17B13 humanized mouse model, designed to advance research in metabolic dysfunction-associated steatotic liver disease (MASLD) and RNA interference (RNAi) therapies.🐁🧬 • ✅ Understanding MASLD: MASLD affects 25% of the global population and can progress to more severe conditions like MASH, cirrhosis, or liver cancer. • ✅ HSD17B13 Target: Learn how targeting HSD17B13 can reduce the risk of chronic liver disease and how RNAi therapies are making strides in treatment development. • ✅ The H11-Alb-hHSD17B13 Mouse Model: Discover how this humanized model accelerates preclinical research, bridging the gap between genetic studies and therapeutic solutions for MASLD and MASH. • Explore how this model accelerates the development of RNAi therapies aimed at reducing liver disease progression. Reach out to Cyagen for collaboration opportunities! • 🔔 Don’t forget to subscribe for more updates on the latest research models and breakthroughs in genetic medicine. • Artificial intelligence services provided by Cyrinn • https://www.cyrinn.cn/ • You can find all our services on our website: https://www.cyagen.com • Follow us on Social Media: • Youtube: / cyagen • Twitter: / cyagenbio • LinkedIn: / cyagen-biosciences • Facebook: https://www.facebook.com/profile.php?... • Email： • [email protected] (Animal Model Services) • [email protected] (Cyagen Catalog Models) • [email protected] (Cell Products and Services)

#############################

New on site